Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Quantitative MR Markers in Non-Myelopathic Spinal Cord Compression: A Narrative Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Estimating Renal Function Following Lung Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of Brace Treatment Using the Soft Brace Spinaposture: A Four-Years Follow-Up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Pradeesh Sivapalan
  • Andras Bikov
  • Charlotte Suppli Ulrik
  • Therese Sophie Lapperre
  • Alexander G Mathioudakis
  • Mats Christian Højberg Lassen
  • Kristoffer Grundtvig Skaarup
  • Tor Biering-Sørensen
  • Jørgen Vestbo
  • Jens-Ulrik S Jensen
Vis graf over relationer

The CORTICO-COP trial showed that eosinophil-guided corticosteroid-sparing treatment for acute exacerbation of chronic obstructive pulmonary disease was non-inferior to standard of care and decreased the accumulated dose of systemic corticosteroids that patients were exposed to by approximately 60%. Smoking status has been shown to affect corticosteroid responsiveness. This post hoc analysis investigated whether eosinophil-guided treatment is non-inferior to conventional treatment in current smokers. The main analysis of current smokers showed no significant difference in the primary endpoint, days alive, and out of hospital within 14 days between the control group (mean, 9.8 days; 95% confidence interval (CI), 8.7-10.8) and the eosinophil-guided group (mean, 8.7 days; 95% CI, 7.5-9.9; p = 0.34). Secondary analyses of the number of exacerbations or deaths, the number of intensive care unit admissions or deaths, lung function improvement, and change in health-related quality of life also showed no significant differences between the two groups. The results of a sensitivity analysis of ex-smokers are consistent with the main analysis. Our results suggest that eosinophil-guided treatment is non-inferior to standard of care in current smokers and ex-smokers. Because data on the impact of smoking status on eosinophil-guided treatments are sparse, more randomised trials are needed to confirm our results.

OriginalsprogEngelsk
Artikelnummer2734
TidsskriftJournal of Clinical Medicine
Vol/bind10
Udgave nummer12
Sider (fra-til)1-11
Antal sider11
ISSN2077-0383
DOI
StatusUdgivet - 21 jun. 2021

ID: 66573543